On Friday Biohaven jumped out with a $100 million IPO filing, after undergoing a radical, low-key revamp of its pipeline focus, clearly aimed at offering investors a chance at a late-stage biotech eyeing near-term FDA applications.

Now, according to the S-1, the New Haven-based biotech’s lead drug is a CGRP therapy for migraine grabbed from Bristol-Myers Squibb. Bristol-Myers Squibb had shelved the drug until Biohaven came along with a new plan to revive it in the clinic.